Amarin


Amarin (AMRN): All Eyes on Vascepa Appeal Verdict

Investors of Amarin (AMRN), the maker of high triglycerides treatment, Vascepa, have had a rough 2020. Despite a strong rebound in April, the …

Judicial Ruling Guts Amarin (AMRN) Stock; What’s Next?

If after seeing Amarin (AMRN) stock tumble 35% over the past year, you consoled yourself with the knowledge that “at least it can’t …

Analyst: With FDA Approval Already Priced In, Avoid Amarin (AMRN) Stock

Today, Amarin (AMRN) investors are scratching their heads as to why the stock tumbled following the announcement that the FDA has approved the …

Oppenheimer Sees Doom and Gloom in Amarin (AMRN) Stock

Buoyed by optimism over the label expansion of Amarin’s (AMRN) flagship drug, Vascepa, the fish oil drug maker’s stock has run off to …

There’s an Opportunity Brewing in Amarin (AMRN) Stock Ahead of Vascepa’s AdCom, Says Analyst

Get in here before November 14, 2019. On this date an FDA Advisory Committee (AdCom) is scheduled to meet to discuss Amarin’s (AMRN) …

Another Day, Another Buy Rating for Amarin (AMRN) Stock

Wall Street loves growth stocks — and for good reason. In 2018, according to Bank of America, “growth” oriented  mutual funds outperformed “value” …

Don’t Say Bye Bye to Amarin (AMRN) Stock, Say Buy Buy

One week ago, Stifel analyst Derek Archila reiterated his “buy” rating on anti-cholesterol drugmaker Amarin (AMRN). He did this partly because he liked …

Amarin (AMRN): Despite Reiterating “Buy” Rating, Stifel Tempers Expectations

In an acronym-heavy update, Stifel analyst Derek Archila reiterated his “buy” rating on anti-cholesterol  drugmaker Amarin Corporation (AMRN) following the company’s Q2 earnings …

Analyst Sings the Praises of Amarin (AMRN) Stock Following ADA Endorsement

With primary care clinicians playing an ever-increasing role in the management of diabetes, staying on top of new developments in the American Diabetes …

Stifel on Amarin (AMRN): Nothing Fishy About This Stock — It’s a Buy!

Do you have high cholesterol? Investors in Amarin (AMRN) kind of hope that you do — but ideally, not too high.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts